Denali Therapeutics Inc. Interest and Other Income
Denali Therapeutics Inc. (DNLI) reported Interest and Other Income of $2.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-06
- Denali Therapeutics Inc. interest and other income for the quarter ending 2026-06-30 was $2.99M, a 72.45% decline year-over-year.
- Denali Therapeutics Inc. interest and other income for the quarter ending 2026-03-31 was $8.91M, a 29.34% decline year-over-year.
- Denali Therapeutics Inc. interest and other income for the quarter ending 2025-12-31 was $8.92M, a 41.18% decline year-over-year.
- Denali Therapeutics Inc. interest and other income for the quarter ending 2025-09-30 was $10.53M, a 34.15% decline year-over-year.
- Denali Therapeutics Inc. interest and other income for fiscal 2025 was $42.90M, a 33.62% decline from fiscal 2024.
- Denali Therapeutics Inc. interest and other income for fiscal 2024 was $64.64M, a 25.49% increase from fiscal 2023.
- Denali Therapeutics Inc. interest and other income for fiscal 2023 was $51.51M, a 248.62% increase from fiscal 2022.
- Denali Therapeutics Inc. interest and other income for fiscal 2022 was $14.77M.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.99M 10-Q · filed 2026-08-06 | $11.90M 10-Q · filed 2026-08-06 | $20.82M derived: sum of 3 quarters · filed 2026-08-06 | $31.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.91M 10-Q · filed 2026-05-07 | $17.83M derived: sum of 2 quarters · filed 2026-05-07 | $28.36M derived: sum of 3 quarters · filed 2026-05-07 | $39.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.45M derived: sum of 2 quarters · filed 2026-02-26 | $30.29M derived: sum of 3 quarters · filed 2026-08-06 | $42.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.53M 10-Q · filed 2025-11-06 | $21.38M derived: sum of 2 quarters · filed 2026-08-06 | $33.99M 10-Q · filed 2025-11-06 | $49.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.84M 10-Q · filed 2026-08-06 | $23.45M 10-Q · filed 2026-08-06 | $38.62M derived: sum of 3 quarters · filed 2026-08-06 | $54.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.61M 10-Q · filed 2026-05-07 | $27.77M derived: sum of 2 quarters · filed 2026-05-07 | $43.77M derived: sum of 3 quarters · filed 2026-05-07 | $61.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.16M derived: sum of 2 quarters · filed 2026-02-26 | $48.72M derived: sum of 3 quarters · filed 2026-02-26 | $64.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.99M 10-Q · filed 2025-11-06 | $33.56M derived: sum of 2 quarters · filed 2025-11-06 | $49.48M 10-Q · filed 2025-11-06 | $62.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $17.57M 10-Q · filed 2025-08-11 | $33.48M 10-Q · filed 2025-08-11 | $46.61M derived: sum of 3 quarters · filed 2026-02-26 | $61.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $15.91M 10-Q · filed 2025-05-06 | $29.04M derived: sum of 2 quarters · filed 2026-02-26 | $43.48M derived: sum of 3 quarters · filed 2026-02-26 | $56.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.57M derived: sum of 2 quarters · filed 2026-02-26 | $40.47M derived: sum of 3 quarters · filed 2026-02-26 | $51.51M 10-K · filed 2026-02-26 |
| 2023-09-30 | $14.44M 10-Q · filed 2024-11-06 | $27.34M derived: sum of 2 quarters · filed 2024-11-06 | $38.38M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $12.90M 10-Q · filed 2024-08-01 | $23.93M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $11.03M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $14.77M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |